scholarly journals Factors Affecting Survival Trend in Colorectal Cancer- A Hospital Based Study

2019 ◽  
Vol 31 (2) ◽  
pp. 12-16
Author(s):  
Md Khalequzzaman Sarker ◽  
Md Moniruzzaman Sarker ◽  
Nasrin Ara Parveen ◽  
Anisur Rahman ◽  
Mohammad Sofiul Kadir ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Cancer Patients ◽  
Median Survival ◽  
Palliative Treatment ◽  
Curative Treatment ◽  
Age Group ◽  
Factors Affecting ◽  
Colorectal Cancer Patients ◽  
Common Malignancy

Colorectal carcinoma is the second most common malignancy and the second leading cause of cancer deaths in Western countries. The condition becomes increasingly common over the age of 50 years. The total number of colorectal cancer patients available for the study within the stipulated time was 56. Among them 64.29% patients were male and 35.71% patients were female. 01.79% patient belonged to age group ≤ 20, 12.5% belonged to age group 21-30, 19.64% belonged to age group 31-40, 25.0% belonged to age group 41-50, 26.79% belonged to age group 51-60, 08.93% belonged to age group 61-70 and 05.35% patients were >70 years of age. Mean age was 48.05 years ± 13.97 SD. In our study, 27.2% survived ≤3 months, 36.4% 4-6 months, 09.1% 7-9 months, 18.2% 10-12 months, 09.1% 13-24 months and 0% >24 months. Among 11 expired patients, 03 got curative treatment and rest of 08 got palliative treatment. Those who got curative treatment, 66.7% survived 10-12 months and 33.3% 13-24 months. Those who got palliative treatment 37.5% survived ≤3 months, 50.0% 4-6 months and 12.5% 7-9 months. Overall median survival was 07 months, for curative treatment 15 months and for palliative treatment 05 months. TAJ 2018; 31(2): 12-16

scholarly journals Factors Affecting The Survival Trend In Oesophageal Malignancy- A Hospital Based Study

2018 ◽  
Vol 27 (1) ◽  
pp. 38-43
Author(s):  
MK Sarker ◽  
MM Sarker ◽  
MFK Bhuiyan ◽  
MMR Khan ◽  
ASMA Raihan
Keyword(s):  
Cancer Patients ◽  
Oesophageal Cancer ◽  
Poor Prognosis ◽  
Palliative Treatment ◽  
Age Groups ◽  
Curative Treatment ◽  
Age Group ◽  
Gastrointestinal Malignancy ◽  
Factors Affecting ◽  
Insidious Onset

Oesophageal cancer is a gastrointestinal malignancy with insidious onset and poor prognosis. The disease predominantly affects the older age groups with pick incidence between 60 to 70 years of age. The total number of oesophageal cancer patients available for the study within the stipulated time was 43. Among them 60.47% patients were male and 39.53% patients were female, 06.98% belonged to age group 31-40, 16.28% belonged to age group 41-50, 37.21% belonged to age group 51-60, 23.25% belonged to age group 61-70 and 16.28% patients were >70 years of age. Mean age was 59.95 years ± 12.63 SD. In our study, 33.3% survived ≤3 months, 09.1% 4–6 months, 15.2 % 7–9 months, 06.1% 10–12 months, 27.2% 13–24 months and 09.1% >24 months. Among the expired patients, 09.10% got curative treatment and rest of 90.90% got palliative treatment. Those who got curative treatment 66.7% survived 13–24 months and 33.3% > 24 months. Those who got palliative treatment 36.7% survived ≤3 months, 10.0% 4–6 months, 06.7% 10–12 months and 30.0% 13–24 months. Overall median survival was 08 months, for curative treatment 18 months and for palliative treatment 07 months.TAJ 2014; 27(1): 38-43

Factors Affecting the Survival Trend in Carcinoma Pancreas- A Hospital Based Study

2020 ◽  
Vol 33 (1) ◽  
pp. 11-16
Author(s):  
Md Khalequzzaman Sarker ◽  
Binoy Paul ◽  
Salahuddin Mohammed Ali Haider ◽  
Md Moniruzzaman Sarker ◽  
Nasrin Ara Parveen ◽  
...  
Keyword(s):  
Median Survival ◽  
Palliative Treatment ◽  
Curative Treatment ◽  
Age Group ◽  
Common Cause ◽  
Factors Affecting ◽  
Carcinoma Pancreas

Carcinoma pancreas is the fourth common cause of the death from cancer in man and women in USA. The condition becomes increasingly common over the age of 70 years. The total number of carcinoma pancreas patients available for the study within the stipulated time was 22. Among them 68.18% patients were male and 31.82% patients were female. 0% belonged to age group ≤ 20, 9.09% belonged to age group 21-30, 18.18% belonged to age group 31-40, 18.18% belonged to age group 41-50, 13.64% belonged to age group 51-60, 27.27% belonged to age group 61-70 and 13.64% patients were >70 years of age. Mean age was 54.87 years ± 17.65 SD. In our study, 46.7% survived ≤3 months, 33.3% 4-6 months, 13.3% 7-9 months, 06.7% 10-12 months, 0% 13-24 months and >24 months. Among 15 expired patients, 02 got curative treatment and rest of 13 got palliative treatment. Those who got curative treatment, 50% survived 7-9 months and 50% 10-12 months. Those who got palliative treatment 53.8% survived ≤3 months, 38.5% 4-6 months and 7.7% 7-9 months. Overall median survival was 04 months, for curative treatment was 09 months and for palliative treatment was 03 months. TAJ 2020; 33(1): 11-16

scholarly journals Factors Affecting The Survival Trend In Carcinoma Stomach- A Hospital Based Study

2018 ◽  
Vol 27 (2) ◽  
pp. 44-49
Author(s):  
MK Sarker ◽  
MM Sarker ◽  
NA Parveen ◽  
PM Basak ◽  
ASMA Raihan
Keyword(s):  
Stomach Cancer ◽  
Poor Prognosis ◽  
Palliative Treatment ◽  
Age Groups ◽  
Curative Treatment ◽  
Age Group ◽  
Gastrointestinal Malignancy ◽  
Factors Affecting ◽  
Insidious Onset ◽  
Carcinoma Stomach

Stomach cancer is a gastrointestinal malignancy with insidious onset and poor prognosis. The disease predominantly affects the older age groups with pick incidence between 60 to 70 years of age. The total number of stomach cancer patients available for the study within the stipulated time was 105. Among them 69.52% patients were male and 30.48% patients were female. 0.95% patient belonged to age group <20, 11.43% belonged to age group 21-30, 09.52% belonged to age group 31-40, 23.81% belonged to age group 41-50, 28.57% belonged to age group 51-60, 20.0% belonged to age group 61-70 and 05.72% patients were >70 years of age. Mean age was 54.91 years ± 13.42 SD. In our study, 45.6% survived <3 months, 15.8% 4–6 months, 07.0% 7–9 months, 14.0% 10–12 months, 10.6% 13–24 months and 07.0% >24 months. Among 57 expired patients, 14 got curative treatment and rest of 43 got palliative treatment. Those who got curative treatment, 36.4% survived 10–12 months, 45.5% 13–24 months and 18.1% > 24 months. Those who got palliative treatment 51.5% survived <3 months, 24.2% 4–6 months, 12.1% 7–9 months, 09.1% 10–12 months and 03.1% 13–24 months. Overall median survival was 06 months, for curative treatment 16 months and for palliative treatment 03 months.TAJ 2014; 27(2): 44-49

Liver metastases of colorectal carcinoma: Prospective study on the use of transarterial chemoembolization (TACE)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4062-4062
Author(s):  
T. J. Vogl ◽  
T. Gruber ◽  
S. Zangos ◽  
J. O. Balzer
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Liver Metastases ◽  
Survival Time ◽  
Cancer Patients ◽  
Median Survival ◽  
Local Control ◽  
Median Survival Time ◽  
Kaplan Meier ◽  
Colorectal Cancer Patients

4062 Background: To evaluate the efficacy of chemoembolization (TACE) in the treatment of liver metastases in colorectal cancer patients concerning local control and survival. Methods: 207 patients with liver metastases of colorectal cancer were treated with repeated TACE in 4-week intervals. In total, 1,307 chemoembolizations were performed with a mean of 6.3 sessions per patient. At the time of first chemoembolization the average age of the patients was 68.8 years (range, 39.4–83.5 years). 158 patients were treated palliatively, 35 symptomatically and 14 patients neoadjuvantly. The chemotherapy consisted of Mitomycin C with/without Gemcitabin; embolization was performed with Lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated by magnetic resonance imaging (MRI). The change in size was calculated and the response was evaluated according to the RECIST criteria. Survival rates from the first diagnosis and from the first TACE session were both calculated according to the Kaplan-Meier method to obtain the median survival. Results: While 70% of the patients showed multiple metastases, 6% had 1 metastasis, 5.8% had 2 metastases and 18.2% had 3 to 4 metastases. Lesion size and number before, during and after treatment were assessed to deduce the morphological response. Local control results according to the RECIST criteria were as follows: partial response 12% of patients, stable disease in 51% and progressive disease in 37%. The 1-year survival rate after TACE was 62%, but the 2-year survival rate had been reduced to 38%. The median survival time from the date of diagnosis of metastases was 3.4 years (according to Kaplan-Meier), the median survival time from the start of TACE treatment was 1.34 years. The median survival time of the palliative group was 1.4 years, of the symptomatic group 0.8 years and of the neoadjuvant group 1.5 years. Conclusions: TACE is an effective minimal-invasive therapy for neoadjuvant, symptomatic or palliative treatment of liver metastases in colorectal cancer patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document